Chris Martin, CEO of ADC Therapeutics.

Chris Martin, DPhil, played an important role in the formation of ADC Therapeutics in 2011 and has served on the company’s Board of Directors since its inception. He has been the Chief Executive Officer and Director of ADC Therapeutics since June 2015.

Founded in 2011 ADC Therapeutics is an unusual European biotechnology "story", in that the founding team has taken the company all the way through the clinic to commercial-stage. They are dedicated to delivering next-generation PBD-Based ADCs for those affected by cancer. 

With a deep understanding of ADC technology and of the oncology treatment landscape, ADC Therapeutics intends to address significant unmet medical needs and improve outcomes for those with difficult-to-treat cancers.

ADC Therapeutics is based in Lausanne, Switzerland, with operations in London (R&D), New Jersey (Clinical and Commercial) and the San Francisco Bay Area (CMC).

Previously, Chris was Co-Founder of Spirogen Ltd and its Chief Executive Officer leading up to the company’s sale to AstraZeneca in October 2013, at which point he became both a member of MedImmune’s Management Leadership Team and AstraZeneca’s Senior Leaders Group. Prior to the acquisition, Chris led numerous Spirogen collaboration transactions, including agreements with Genentech and Seattle Genetics.

Chris is a Fellow of the Institution of Chemical Engineers and a Sainsbury Management Fellow.